BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma
BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma
About this item
Full title
Author / Creator
Shao, Y and Aplin, A E
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
B-RAF is mutated to a constitutively active form in 8% of human cancers including 50% of melanomas. In clinical trials, the RAF inhibitor, PLX4032 (vemurafenib), caused partial or complete responses in 48–81% of mutant B-RAF harboring melanoma patients. However, the average duration of response was 6–7 months before tumor regrowth, indicating the a...
Alternative Titles
Full title
BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3504716
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3504716
Other Identifiers
ISSN
1350-9047
E-ISSN
1476-5403
DOI
10.1038/cdd.2012.94
